The Prognostic and Predictive Value of Body Mass Index in Patients with HR+/HER2− Breast Cancer Treated with CDK4/6 Inhibitors: A Systematic Literature Review
Larisa Maria Badau, Cristina Marinela Oprean, Andrei Dorin Ciocoiu, Paul Epure, Brigitha Vlaicu · 2025
Read The Prognostic and Predictive Value of Body Mass Index in Patients with HR+/HER2− Breast Cancer Treated with CDK4/6 Inhibitors: A Systematic Literature Review by Larisa Maria Badau, Cristina Marinela Oprean, Andrei Dorin Ciocoiu, Paul Epure, Brigitha Vlaicu (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12784732.txt.
Description
Larisa Maria Badau and co-authors review, in twenty twenty-five, whether body mass index predicts outcomes for a common breast cancer treated with CDK4/6 inhibitors. These drugs, plus hormone therapy, are standard for hormone-positive, HER2-negative metastatic disease. Body fat affects hormones and the drugs' targets, so BMI might matter. The team searched two databases for studies from twenty fifteen to twenty twenty-five. They kept real-world studies and cohorts that linked BMI or body composition to survival on these drugs. Fourteen of sixty-nine records qualified.
Findings were mixed. Four studies found better survival at higher BMI; most found no clear link. Scan-based measures, such as visceral fat and muscle area, predicted prognosis more reliably than BMI alone, the review concludes.
Catalog record
| CREATOR | Larisa Maria Badau, Cristina Marinela Oprean, Andrei Dorin Ciocoiu, Paul Epure, Brigitha Vlaicu |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 31 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |